MSD, Cipla form Strategic Partnership to sell HIV drug in India

20 Feb 2014 Evaluate

Cipla, India’s second-largest drug maker by market share has formed an India-specific strategic partnership with MSD, one of the world’s leading players in HIV innovative treatment. Within the scope of the partnership, Cipla will have a non-exclusive license to market, promote and distribute MSD’s raltegravir 400mg tablet, under a different brand name in India.

With its history of over 75 years, Cipla has a formidable operation reaching the far corners of the country and therefore is well placed to ensure this key medication reaches the patients who need it. Access to treatment and patient centric approach are cornerstone to this partnership, with this model both companies expect to broaden reach of raltegravir in private and public markets in India. Access to raltegravir is important for patients who require it as part of third line salvage regimen where there are few options left.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.

Cipla Share Price

1397.95 -36.65 (-2.55%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×